Cytosorbents (CTSO) Cash from Investing Activities Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 40.30% |
| Dec 31, 2025 | -1.80% |
| Sep 30, 2025 | 16.39% |
| Jun 30, 2025 | 23.30% |
| Mar 31, 2025 | 37.89% |
| Dec 31, 2024 | 21.01% |
| Sep 30, 2024 | 1.06% |
| Jun 30, 2024 | 18.32% |
| Mar 31, 2024 | 23.16% |
| Dec 31, 2023 | 15.92% |
| Sep 30, 2023 | 1.37% |
| Jun 30, 2023 | 18.26% |
| Mar 31, 2023 | -7.65% |
| Dec 31, 2022 | 18.75% |
| Sep 30, 2022 | -5.85% |
| Jun 30, 2022 | -67.77% |
| Mar 31, 2022 | -32.91% |
| Dec 31, 2021 | -76.32% |
| Sep 30, 2021 | -78.87% |
| Jun 30, 2021 | -19.95% |
| Mar 31, 2021 | -8.41% |
| Dec 31, 2020 | 10.68% |
| Sep 30, 2020 | -18.95% |
| Jun 30, 2020 | -7.48% |
| Mar 31, 2020 | 14.83% |
| Dec 31, 2019 | -15.74% |
| Sep 30, 2019 | 34.74% |
| Jun 30, 2019 | -29.29% |
| Mar 31, 2019 | 36.98% |
| Dec 31, 2018 | -14.52% |
| Sep 30, 2018 | -75.02% |
| Jun 30, 2018 | -68.37% |
| Mar 31, 2018 | -193.03% |
| Dec 31, 2017 | -100.75% |
| Sep 30, 2017 | -155.30% |
| Jun 30, 2017 | -88.68% |
| Mar 31, 2017 | -78.51% |
| Dec 31, 2016 | -181.44% |
| Sep 30, 2016 | 35.99% |
| Dec 31, 2015 | -26.88% |
| Sep 30, 2015 | 169.70% |